Media about us

28 January 2015

Oppenheimer Analyst Rohit Vanjani's 2015 Pipeline: Pot, Pain, and Babies

Streetwise Reports

Building on another blockbuster year in specialty pharmacy and generics, Rohit Vanjani, a senior analyst at Oppenheimer & Co., has reason to be excited for 2015. Vanjani specializes in nurturing firms developing novel ways to treat some of humanity's most persistent medical problems, and in this interview with The Life Sciences Report, he describes some of the most promising therapies, and companies, in the life sciences sector.

27 January 2015

NovaMedica gets Russian rights for three gastrointestinal products from Omega Pharma

PRB Production and Manufacturing

NovaMedica and Belgian pharmaceutical firm Omega Pharma have signed a partnership agreement to promote, distribute and sell a line of OTC gastrointestinal products under Benegast brand in Russia.

11 December 2014

Vaccine May Prevent Antibiotic Resistant Skin Infections

Drud Discovery&Development

A study reported in the Proceedings of the National Academy of Sciences USA holds new hope for preventing or reducing the severity of infections caused by the “superbug” MRSA.  In the study, infectious disease specialists at the Los Angeles Biomedical Research Institute reported that a new investigational vaccine, NDV-3 (licensed to NovaDigm Therapeutics, Inc.), employing the recombinant protein Als3, can mobilize the immune system to fight off MRSA skin infections in an experimental mode.

03 December 2014

Medical device makers hope to kill a tax

Bernard J. Wolfson, Orange County Register

The issue has keen interest in Orange County, a hotbed of medical device manufacturing with more than 250 firms employing tens of thousands of people.

23 October 2014

Neothetics Files $63M IPO to Advance Drug That Melts “Love Handles”

Bruce V. Bigelow, Xconomy

A biotech company developing an injectable drug to shrink the excess fat that forms “love handles” says it plans to raise more than $63 million through an IPO.

09 October 2014

High Potential for New Products

Anatoly Medetsky, The Moscow Times

NovaMedica is a $760 million joint venture between Rusnano and Domain Associates to develop new drugs in Russia. It's managed by RMI Partners. Anatoly Medetsky spoke to CEO Vladimir Gurdus. 

07 October 2014

How a U.S. VC firm keeps doing business with Russia

Dan Primack, Fortune

Around four years ago, a group of U.S. venture capitalists headed to Russia on a state-sponsored trip that was designed to promote foreign investment in the nation’s startups. One of the most impressed VCs was Brian Dovey, a longtime partner with healthcare-focused DomainAssociates. He remained in touch with the Russian organizers, and in Domain later announced a $760 million partnership with Rusnano, a government-owned investment fund in Russia.

02 October 2014

Horus Pharma and NovaMedica Sign Agreement to Market a Portfolio of Eye Care Products in Russia

MarketWatch

NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS).

26 August 2014

New eye implant could replace glasses

Sharon Marris, Express

Reading glasses may become a thing of the past as a new implant revolutionises treatment for ageing eyes.

26 August 2014

Implant means end of reading glasses is in sight

Sarah Knapton, Science Correspondent / The Telegraph

Scientists have developed a tiny implant, no bigger than a pinhead, which sits inside the cornea and slightly increases its curvature, to allow the eye to focus again.